Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Data
Jazyk angličtina Země Velká Británie, Anglie Médium electronic-ecollection
Typ dokumentu dopisy, práce podpořená grantem, Research Support, N.I.H., Extramural
Grantová podpora
K23 HL161271
NHLBI NIH HHS - United States
P30 DK092926
NIDDK NIH HHS - United States
P30 AG024824
NIA NIH HHS - United States
PubMed
38708405
PubMed Central
PMC11067965
DOI
10.5334/gh.1323
Knihovny.cz E-zdroje
- Klíčová slova
- aspirin, cardiovascular disease, non-communicable disease, prevention,
- MeSH
- Aspirin * terapeutické užití aplikace a dávkování MeSH
- celosvětové zdraví * MeSH
- inhibitory agregace trombocytů terapeutické užití MeSH
- kardiovaskulární nemoci * prevence a kontrola epidemiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- prevalence MeSH
- primární prevence * metody MeSH
- průřezové studie MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- Názvy látek
- Aspirin * MeSH
- inhibitory agregace trombocytů MeSH
Africa Health Research Institute Somkhele and Durban South Africa
Center for Clinical Management Research VA Ann Arbor Healthcare System Ann Arbor MI USA
Center for Indigenous Health Research Wuqu'Kawoq Tecpán Guatemala
Centre For Chronic Disease Control New Delhi India
Centre for Global Surgery Department of Global Health Stellenbosch University Cape Town South Africa
Chan Zuckerberg Biohub San Francisco San Francisco California USA
Department of Internal Medicine MKPGMS Uganda Martyrs University Kampala
Department of Internal Medicine University of Michigan Ann Arbor MI USA
Department of Medicine 2 1st Faculty of Medicine Charles University Prague Prague Czechia
Department of Medicine and Global Health Center Washington University in St Louis St Louis MO USA
Department of Preventive Medicine Northwestern University Feinberg School of Medicine Chicago IL USA
Division of Global Health Equity Brigham and Women's Hospital Boston MA USA
Division of Infectious Diseases Brigham and Women's Hospital Harvard Medical School Boston MA USA
Division of Non Communicable Diseases Ministry of Health Nairobi Kenya
Division of Primary Care and Population Health Stanford University USA
EPIUnit Institute of Public Health University of Porto Porto Portugal
Faculty of Medicine and Health Sciences Universidade Nacional Timor Lorosa'e Dili Timor Leste
Faculty of Medicine Eduardo Mondlane University Maputo Mozambique
Harvard Center for Population and Development Studies Harvard University Cambridge USA
Health Research and Epidemiology Unit Ministry of Health Thimphu Bhutan
Institute for Applied Health Research University of Birmingham UK
ITR Laboratory for Integrative and Translational Research in Population Health Porto Portugal
Kiel Institute for the World Economy Kiel Germany
Nucleo de Investigaçao Departamento de Medicina Hospital Central do Maputo Maputo Mozambique
Nutrition Department National Center for Public Health Ulaanbaatar Mongolia
Professorship of Behavioral Sciences in Prevention and Care Technical University of Munich Germany
Public Health Department Petre Shotadze Tbilisi Medical Academy Georgia
Public Health Promotion and Development Organization Kathmandu Nepal
St Francis Hospital Nsambya Kampala Uganda
The George Institute for Global Health University of New South Wales Sydney Australia
The Institute of Global Health Faculty of Medicine University of Geneva Geneva Switzerland
Zobrazit více v PubMed
Arnett, DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019; 140: e596–646. DOI: 10.1161/CIR.0000000000000678 PubMed DOI PMC
Yoo SGK, Chung GS, Bahendeka SK, Sibai AM, Damasceno A, Farzadfar F, et al. Aspirin for secondary prevention of cardiovascular disease in 51 low-, middle-, and high-income countries. JAMA. 2023; 330: 715–24. DOI: 10.1001/jama.2023.12905 PubMed DOI PMC
The WHO CVD Risk Chart Working Group, Kaptoge S, Pennells L, Bacquer DD, Cooney MT, Kavousi M, et al. World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. Lancet Global Health. 2019; 7: e1332–45. DOI: 10.1016/S2214-109X(19)30318-3 PubMed DOI PMC
The World Bank. World Bank Country and Lending Groups n.d. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed January 18, 2023).
Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, et al. Estimating longitudinal risks and benefits from cardiovascular preventive therapies among medicare patients. Circulation. 2017; 135: e793–813. DOI: 10.1161/CIR.0000000000000467 PubMed DOI PMC
Dehmer SP, O’Keefe LR, Evans CV, Guirguis-Blake JM, Perdue LA, Maciosek MV. Aspirin use to prevent cardiovascular disease and colorectal cancer. JAMA. 2022; 327: 1598–607. DOI: 10.1001/jama.2022.3385 PubMed DOI
Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: Understanding time lags in translational research. Journal of the Royal Society of Medicine. 2011; 104: 510–20. DOI: 10.1258/jrsm.2011.110180 PubMed DOI PMC